ChiCTR2100053440 版本V1.3 版本创建时间2022/09/27 05:52:24 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100053440 

最近更新日期:

Date of Last Refreshed on:

2022-05-18 20:17:38 

注册时间:

Date of Registration:

2021-11-21 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

同期三尖瓣手术与左心辅助装置

Public title:

Concomitant tricuspid valve surgery in left ventricular assist device implantation

注册题目简写:

English Acronym:

研究课题的正式科学名称:

同期三尖瓣手术对左心室辅助装置植入患者的影响

Scientific title:

Impact of concomitant tricuspid valve surgery during left ventricular assist device implantation

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

帖红涛 

研究负责人:

帖红涛 

Applicant:

Tie Hongtao 

Study leader:

Tie Hongtao 

申请注册联系人电话:

Applicant telephone:

+86 491 628713419

研究负责人电话:

Study leader's
telephone:

+86 491 628713419

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

ht_tie@hospital.cqmu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

ht_tie@hospital.cqmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

https://www.hospital-cqmu.com/sy.htm

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

https://www.hospital-cqmu.com/sy.htm

申请注册联系人通讯地址:

重庆市渝中区袁家岗友谊路1号

研究负责人通讯地址:

重庆市渝中区袁家岗友谊路1号

Applicant address:

1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing

Study leader's address:

1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing

申请注册联系人邮政编码:

Applicant postcode:

400016

研究负责人邮政编码:

Study leader's postcode:

400016

申请人所在单位:

明斯特大学医院和重庆医科大学附属第一医院

Applicant's institution:

Münster University Hospital and the First Affiliated Hospital of Chongqing Medical University

研究负责人所在单位:

明斯特大学医院和重庆医科大学附属第一医院

Affiliation of the Leader:

Münster University Hospital and the First Affiliated Hospital of Chongqing Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2021-879-f-S

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

University Hospital Muenster 和 重庆医科大学附属第一医院伦理委员会

Name of the ethic committee:

ethics committee of the Westfalen-Lippe Medical Association and the Westf?lischen Wilhelms-Universit?t Münster

伦理委员会批准日期:

Date of approved by ethic committee:

2020-12-11 00:00:00

伦理委员会联系人:

Sabrina Martens

Contact Name of the ethic committee:

Sabrina Martens

伦理委员会联系地址:

Albert-Schweitzer-Campus 1

Contact Address of the ethic committee:

Albert-Schweitzer-Campus 1

伦理委员会联系人电话:

Contact phone of the ethic committee:

+49 251 9292460

伦理委员会联系人邮箱:

Contact email of the ethic committee:

ethik-kommission@aekwl.de

研究实施负责(组长)单位:

University Hospital Muenster

Primary sponsor:

No sponsor

研究实施负责(组长)单位地址:

Albert-Schweitzer-Campus 1

Primary sponsor's address:

None

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

德国

省(直辖市):

Nordrhein-Westfalen

市(区县):

Münster

Country:

Germany

Province:

Nordrhein-Westfalen

City:

单位(医院):

明斯特大学医院

具体地址:

Albert-Schweitzer-Campus 1

Institution
hospital:

University Hospital Münster

Address:

Albert-Schweitzer-Campus 1

国家:

中国

省(直辖市):

重庆

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆医科大学附属第一医院

具体地址:

渝中区袁家岗友谊路1号

Institution
hospital:

The First Affiliated Hospital of Chongqing Medical University

Address:

1 Youyi Road, Yuanjiagang, Yuzhong District

经费或物资来源:

Source(s) of funding:

None

研究疾病:

终末期心力衰竭  

Target disease:

End-stage heart failure

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

研究同期 TVS 对接受 LVAD 植入术患者临床结果的影响。  

Objectives of Study:

to investigate the effect of concomitant TVS on the clinical outcomes in patients undergoing LVAD implantation.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

所有在我们机构接受 CF-LVAD 植入的成年患者,且术前超声证实为中重度三尖瓣反流(TR)。

Inclusion criteria

All adult patients who received CF-LVAD implantation in our institution were retrieved, patients were diagnosed as moderate-to-severe TR.

排除标准:

1.有 LVAD 植入历史的患者;
2.接受 LVAD 翻修的患者;
3.LVAD 植入前接受心脏移植的患者;
4.接受 BiVAD 支持的患者;
5.超声心动图确定的无中重度 TR 患者。

Exclusion criteria:

1. Patients with a history of LVAD implantation;
2. Patients undergoing LVAD revision;
3. Patients who received heart transplantation before LVAD implantation;
4. Patients receiving BiVAD support;
5. Patients without moderate to severe TR as determined by echocardiography.

研究实施时间:

Study execute time:

From 2021-11-04 00:00:00 To 2021-12-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-11-30 00:00:00 To 2021-11-30 00:00:00

干预措施:

Interventions:

组别:

三尖瓣手术组

样本量:

36

Group:

Tricuspid valve surgery group

Sample size:

干预措施:

同期三尖瓣手术

干预措施代码:

Intervention:

Concurrent tricuspid valve surgery during LVAD implantation

Intervention code:

组别:

非三尖瓣手术

样本量:

32

Group:

Non-tricuspid valve surgery group

Sample size:

干预措施:

植入LVAD期不行三尖瓣手术

干预措施代码:

Intervention:

no tricuspid valve surgery was performed during LVAD implantation

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

德国

省(直辖市):

Nordrhein-Westfalen 

市(区县):

Münster 

Country:

Germany

Province:

Nordrhein-Westfalen

City:

Münster

单位(医院):

明斯特大学医院 

单位级别:

 

Institution
hospital:

University Hospital Münster

Level of the institution:

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆医科大学附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Chongqing Medical University

Level of the institution:

Teritary A

测量指标:

Outcomes:

指标中文名:

死亡

指标类型:

主要指标

Outcome:

Mortality

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

右心衰竭

指标类型:

主要指标

Outcome:

Right heart failure

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

急性肾损伤

指标类型:

主要指标

Outcome:

acute kidney injury

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 19 years
最大 Max age 99 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

非随机对照研究

Randomization Procedure (please state who generates the random number sequence and by what method):

Not randomized study

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

不适用

Blinding:

Not available

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

邮箱联系

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Excel

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

每个病例有数据收集表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Every patient has a CRF with Excel.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-11-21 12:09:33